Home > Boards > US Listed > Biotechs >

BioLineRx Ltd. (BLRX)

BLRX RSS Feed
Add BLRX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/12/2022 1:20:12 AM - Followers: 120 - Board type: Free - Posts Today: 0

BIOLINERX
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

BioLineRx's close ties with universities, research institutes, academic institutions, technology transfer offices and biotechnology companies, both in Israel and globally, enable access to promising projects at an early stage. The first stage involves a stringent selection process. BioLineRx's scientists specialize in evaluating potential drug candidates from both scientific and marketing perspectives. After acquiring the most promising projects, the Company then performs feasibility assessment studies and development through pre-clinical and clinical stages. Supported and assisted by a distinguished panel of scientific advisers, the Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance BioLineRx’s pipeline usually through Phase II proof of concept in humans. And finally, the Company partners with medium size and large pharmaceutical companies to complete the clinical development and bring the product to market.
 
BioLineRx also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator for the development of pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.

==============================

HIGHLIGHTS:: BioLineRx Ltd.(BLRX)

BL-7040 (IBD) – Received positive results from a Phase 2 proof-of-concept study to evaluate the effectiveness of BL-7040 for the treatment of inflammatory bowel disease (IBD)

Immediate next steps include evaluating the most advantageous ways to progress with this therapeutic candidate from a clinical and business perspective, including examining potential additional indications. Plans also include accelerating discussions with potential co-development and licensing partners.

BL-8040 (AML) – Received U.S. regulatory approvals to commence a Phase 2a trial for the treatment of relapsed/refractory acute myeloid leukemia (AML); trial to be conducted at three sites in the U.S. and five sites in Israel, with initial patient enrollment expected in Q2 2013; partial results expected in Q4 2013 and final results expected in the second half of 2014

BL-1040 (ventricular remodeling) – Recruitment commenced at U.S. sites for the PRESERVATION I clinical trial, a CE Mark registration trial for BL-1040 (BCM), a novel medical device for the prevention of ventricular remodeling following an acute myocardial infarction; there are currently multiple active sites recruiting in six countries

BL-5010 (skin lesions) – Reached final stages of development for proprietary pen-like applicator for BL-5010, a novel formulation of two acids being developed for the non-surgical removal of skin lesions; planning to commence pivotal CE-Mark registration trial for European approval in the second half of 2013

BL-8020 (HCV) – Commenced a Phase 1/2 clinical trial to evaluate the effectiveness of an orally-available, interferon-free treatment for Hepatitis C (HCV) at two sites in France, following approval from the French regulatory authorities; partial results expected in Q4 2013; final results expected in the first half of 2014

BL-1020 (schizophrenia) – Disappointing results of interim analysis for the Phase 2/3 CLARITY trial led to termination of the trial; full unblinded study data is expected during Q3 2013

BL-9010 (severe asthma) – Added a novel, bi-specific antibody for the treatment of severe and persistent asthma to the main therapeutic pipeline, following promising pre-clinical data

Capital Raise – $8 million direct equity placement to the OrbiMed Group was completed in February 2013


“In the past few months, we have seen major progress on a number of clinical and pre-clinical programs in our pipeline, which offer exciting opportunities to address unmet medical needs in a wide range of therapeutic areas. We believe our active programs offer significant potential for patients around the world, as well as for the future success of our Company and its shareholders,” stated Kinneret Savitsky, Ph.D, Chief Executive Officer of BioLineRx. “In the third quarter of this year, we expect to receive a full analysis of the unblinded study data for all participants in the CLARITY Phase 2/3 trial for BL-1020. While we discontinued this clinical trial in mid-March based on disappointing results of the interim analysis, we will not decide the future of the overall BL-1020 program until we have carried out a more thorough review of the full unblinded results.”

“The PRESERVATION I study being conducted by our partner, Ikaria, for BL-1040, for the treatment of ventricular remodeling post-AMI, is moving forward at full steam, with multiple sites in six countries around the world actively recruiting, including a number of sites in the U.S. BL-1040 remains one of our leading compounds, with significant clinical data expected to be reported next year, and we hope that it will eventually offer a great benefit to heart attack patients,” continued Dr. Savitsky.

“We continue to accelerate development of our clinical pipeline, with three of our compounds completing significant milestones since the beginning of the year. Our BL-7040 compound for IBD completed a Phase 2a open-label, proof-of-concept study with very encouraging and positive results. We are now evaluating next steps for BL-7040 in order to identify the best way to move forward from both a clinical and business perspective, including examining potential additional indications. In parallel, we are also planning to accelerate discussions with potential co-development and licensing partners for this asset.”

“In addition, BL-8040, for hematological cancers, one of our most exciting programs, just received FDA approval to commence a Phase 2a trial for the treatment of relapsed/refractory AML. We are excited to initiate this multicenter, open-label study under an IND, which will be conducted in the U.S. and Israel, and will enroll up to 50 patients. MD Anderson Cancer Center in Houston will be the initial site for this trial, with two additional premier sites in the US and five other well-known sites in Israel expected to participate. We believe the excitement surrounding the trial, especially at these particular sites, is a testament to the need for an AML therapy, as well as the potential of BL-8040 shown in the previous pre-clinical and clinical data.”

“Finally, we recently reported enrollment of the first patient in our Phase 1/2 trial for BL-8020, an oral treatment for HCV, at a leading hospital in Paris, France. We look forward to partial results from the trial in the fourth quarter of 2013, as well as final results in the first half of 2014. I would also like to point out that as our pipeline evolves, we continue to replenish our pre-clinical pipeline with the addition of promising assets, such as BL-9010 for the treatment of severe and persistent asthma, which recently graduated from our Early Development Program,” concluded Dr. Savitsky



Link To Interview with BioLineRX VP Of Business Development:
http://www.pharmatelevision.com/Video/1176-PTVNRDavidMalek.aspx



biolinerx.com -  BioLineRX Website




BLRX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BLRX News: H.C. Wainwright Thinks Biolinerx’s Stock is Going to Recover 03/16/2022 07:15:21 AM
BLRX News: Annual and Transition Report (foreign Private Issuer) (20-f) 03/16/2022 03:26:34 AM
BLRX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 03/16/2022 03:12:11 AM
BLRX News: biolinerx GAAP EPS of -$0.04 beats by $0.42 03/16/2022 03:07:23 AM
BLRX News: BioLineRx posts more data to support potential of stem cell mobilization agent 03/03/2022 05:24:04 AM
PostSubject
#2409   BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q1 midastouch017 05/12/22 01:20:12 AM
#2408   BioLineRx Reports First Quarter 2022 Financial Results and midastouch017 05/11/22 07:55:09 AM
#2407   biolinerx Q1 2022 Earnings Preview midastouch017 05/10/22 12:30:22 PM
#2406   BioLineRx to Report First Quarter 2022 Results on midastouch017 05/05/22 08:31:25 AM
#2405   BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q4 midastouch017 03/16/22 03:12:53 PM
#2404   biolinerx GAAP EPS of -$0.04 beats by $0.42 midastouch017 03/16/22 09:10:25 AM
#2403   BioLineRx Reports Year-End 2021 Financial Results and Provides midastouch017 03/16/22 09:05:21 AM
#2402   BioLineRx to Report 2021 Annual Results on March midastouch017 03/10/22 08:02:59 AM
#2401   BioLineRx posts more data to support potential of midastouch017 03/03/22 10:53:10 AM
#2400   BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study midastouch017 03/03/22 07:54:51 AM
#2399   BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide midastouch017 01/31/22 12:57:13 PM
#2398   BioLineRx Announces Completion of Enrollment of Phase 1/2a midastouch017 01/24/22 08:03:16 AM
#2397   Biolinerx (BLRX) Receives a Buy from H.C. Wainwright midastouch017 01/19/22 05:49:20 AM
#2396   BioLineRx gains on update for pre-NDA meeting with midastouch017 01/18/22 09:17:05 AM
#2395   BioLineRx Announces Successful Completion of Pre-NDA Meeting with midastouch017 01/18/22 08:16:58 AM
#2394   BioLineRx Provides Highlights from Oral Presentation Delivered at midastouch017 12/17/21 08:08:23 AM
#2393   BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (S midastouch017 12/15/21 08:26:33 AM
#2392   475 Motixafortide (BL-8040) and G-CSF Versus Placebo and midastouch017 12/13/21 04:40:06 AM
#2391   Stock Traders Purchase Large Volume of Call Options midastouch017 12/12/21 10:41:08 AM
#2390   Let's go Brando Docstemcell2020 12/10/21 02:32:21 PM
#2389   why? Toasted_oats 12/10/21 01:14:41 PM
#2388   2.7050+0.4350 (+19.1630%) midastouch017 12/10/21 12:07:19 PM
#2387   2.7802+0.5102 (+22.4758%) midastouch017 12/10/21 11:32:33 AM
#2386   Great article: midastouch017 11/22/21 12:19:55 AM
#2385   Guys/gals....I found this new article on BLRX. It andyxtreme 11/21/21 12:47:59 PM
#2384   BioLineRx Reports Third Quarter 2021 Financial Results and midastouch017 11/18/21 08:35:29 AM
#2383   see you are still here. don't like wishing makingitnow 11/14/21 05:36:53 PM
#2382   BioLineRx to Report Third Quarter 2021 Results on midastouch017 11/12/21 08:19:30 AM
#2381   BioLineRx Announces an Oral Presentation and Three Poster midastouch017 11/04/21 09:33:03 AM
#2380   BioLineRx Ltd. (NASDAQ: BLRX), a late clinical-stage biopharmaceutical midastouch017 10/14/21 08:38:54 AM
#2379   BioLineRx shares rise 8% after Motixafortide multiple myeloma midastouch017 10/13/21 10:20:51 AM
#2378   BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning midastouch017 10/13/21 08:42:58 AM
#2377   BioLineRx Ltd. (NASDAQ:BLRX) midastouch017 10/06/21 05:36:30 AM
#2376   BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 midastouch017 08/18/21 12:27:57 PM
#2375   BioLineRx Reports Second Quarter 2021 Financial Results and midastouch017 08/18/21 07:57:40 AM
#2374   BioLineRx Reports Second Quarter 2021 Financial Results and midastouch017 08/18/21 07:57:03 AM
#2373   Glad to have found this board and some frankyahoo 07/01/21 05:07:10 PM
#2372   Thanks for the accessible information. I am starting microchips 07/01/21 12:01:14 PM
#2371   BioLineRx: A Top Candidate For A Takeover Before midastouch017 07/01/21 01:45:41 AM
#2370   There is a SA article: BioLineRx: A Top someconcerns 06/30/21 06:10:43 PM
#2369   Here we are again. what up with the makingitnow 06/30/21 05:19:22 PM
#2368   Thank you, Mali. In closing, as is our midastouch017 05/26/21 12:22:51 PM
#2367   BioLineRx Ltd.'s (BLRX) CEO Phil Serlin on Q1 midastouch017 05/26/21 12:19:27 PM
#2366   BioLineRx Reports First Quarter 2021 Financial Results and midastouch017 05/26/21 07:37:48 AM
#2365   BioLineRx to Report First Quarter 2021 Results on midastouch017 05/20/21 08:44:22 AM
#2364   Filled gap up from other day this morning Runners123 05/11/21 11:20:13 AM
#2363   $3.50 was the bottom/support, maybe now that the tobias89 05/08/21 08:17:18 PM
#2362   Had to pull the trigger and take my murocman 05/07/21 09:56:46 AM
#2361   * * $BLRX Video Chart 05-05-2021 * * ClayTrader 05/05/21 05:04:21 PM
#2360   Everyone who had been holding did very well cjstocksup 05/04/21 05:12:09 PM
PostSubject
Consent Preferences